Thu Dec 26 08:48:39 UTC 2024: ## Indian Pharma Industry Poised for Explosive Growth, Driven by Innovation and Technology
**NEW DELHI** – India’s pharmaceutical industry is on the verge of a dramatic transformation, poised to nearly double in size by 2030, reaching a projected US$120-130 billion, according to industry leaders. This surge is fueled by advancements in artificial intelligence (AI), machine learning, and precision medicine, alongside supportive government policies and a burgeoning pool of digital talent.
The Indian Pharmaceutical Alliance (IPA), representing major players like Sun Pharma and Cipla, and the Organisation of Pharmaceutical Producers of India (OPPI), representing companies like AstraZeneca and Novartis, both forecast significant growth. This growth will be driven by increased investment in research and innovation, particularly in areas like CAR-T cell therapy, mRNA vaccines, and complex molecule development. The impending expiry of blockbuster biologic patents also presents a significant opportunity in the biosimilars market.
IPA Secretary General Sudarshan Jain highlighted the government’s upcoming Promotion of Research & Innovation Programme as a key catalyst for growth, while noting that leading companies are already expanding into higher-value drugs and specialty portfolios. OPPI Director General Anil Matai emphasized the importance of strengthened regulatory frameworks to ensure the safe and swift adoption of innovative therapies. Both organizations stressed the commitment to establishing India as a global hub for high-quality, affordable pharmaceuticals.
Beyond pharmaceuticals, the Indian healthcare sector is also experiencing robust expansion. Fortis Healthcare projects the hospital market to grow to US$194 billion by 2032, driven by an aging population and increased demand for specialized geriatric and preventive care. The med-tech sector, projected to reach US$50 billion by FY30, is also experiencing significant growth, fueled by R&D investment and favorable government policies. Similarly, the diagnostics industry, expected to reach US$25 billion by FY28, anticipates growth driven by increased awareness of preventive healthcare and broader insurance coverage. Leaders across these sectors emphasized the importance of technology integration, including AI and data analytics, to further enhance efficiency and patient care. Consolidation through mergers and acquisitions is also expected to play a significant role in shaping the future of the industry.
First Piper 